Online citations, reference lists, and bibliographies.
← Back to Search

In Vitro Characterization Of Cationic Copolymer-complexed Recombinant Human Butyrylcholinesterase.

C. Pope, Chibuzor Uchea, N. Flynn, Kirstin Poindexter, Liyi Geng, W. S. Brimijoin, S. Hartson, A. Ranjan, J. Ramsey, J. Liu
Published 2015 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Effective use of exogenous human BChE as a bioscavenger for organophosphorus toxicants (OPs) is hindered by its limited availability and rapid clearance. Complexes made from recombinant human BChE (rhBChE) and copolymers may be useful in addressing these problems. We used in vitro approaches to compare enzyme activity, sensitivity to inhibition, stability and bioscavenging capacity of free enzyme and copolymer-rhBChE complexes (C-BCs) based on one of nine different copolymers, from combinations of three molecular weights (MW) of poly-L-lysine (PLL; high MW, 30-70 kDa; medium MW, 15-30 kDa; low MW, 4-15 kDa) and three grafting ratios of poly(ethylene glycol) (PEG; 2:1, 10:1, 20:1). Retarded protein migration into acrylamide gels stained for BChE activity was noted with all copolymers as the copolymer-to-protein ratio was increased. BChE activity of C-BCs was lower relative to free enzyme, with the 2:1 grafting ratio showing generally greater reduction. Free enzyme and C-BCs showed relatively similar in vitro sensitivity to inhibition by paraoxon, but use of the 20:1 grafting ratio led to lower potencies. Through these screening assays we selected three C-BCs (high, medium and low MW; 10:1 grafting) for further characterizations. BChE activity was higher in C-BCs made with the medium and low compared to high MW-based copolymer. C-BCs generally showed higher stability than free enzyme when maintained for long periods at 37 °C or following incubation with chymotrypsin. Free enzyme and C-BCs were similarly effective at inactivating paraoxon in vitro. While these results are promising for further development, additional studies are needed to evaluate in vivo performance.
This paper references
10.1016/J.CBI.2005.10.028
Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice.
A. Saxena (2005)
10.1517/14712598.3.8.1253
Chemical and biological properties of polymer-modified proteins
G. Kochendoerfer (2003)
10.1111/j.1399-6576.1988.tb02727.x
Half–life of plasma cholinesterase
D. Østergaard (1988)
10.1016/j.cbi.2013.04.010
Inhibition of porcine liver carboxylesterase by phosphorylated flavonoids.
Yingling Wei (2013)
10.1124/mol.109.055665
Adenovirus-Transduced Human Butyrylcholinesterase in Mouse Blood Functions as a Bioscavenger of Chemical Warfare Nerve Agents
N. Chilukuri (2009)
10.1021/acsami.5b05228
Terminal PEGylated DNA–Gold Nanoparticle Conjugates Offering High Resistance to Nuclease Degradation and Efficient Intracellular Delivery of DNA Binding Agents
L. Song (2015)
10.1016/0003-2697(75)90423-6
A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations.
C. Johnson (1975)
10.1016/0006-2952(61)90145-9
A new and rapid colorimetric determination of acetylcholinesterase activity.
G. Ellman (1961)
10.1124/JPET.102.033746
Wild-Type and A328W Mutant Human Butyrylcholinesterase Tetramers Expressed in Chinese Hamster Ovary Cells Have a 16-Hour Half-Life in the Circulation and Protect Mice from Cocaine Toxicity
E. Duysen (2002)
10.1208/s12249-014-0143-6
Nanoparticle Ligand Presentation for Targeting Solid Tumors
J. Duskey (2014)
10.1016/j.ntt.2012.02.002
Characterization of human serum butyrylcholinesterase in rhesus monkeys: behavioral and physiological effects.
Todd M. Myers (2012)
10.1016/j.ejpb.2012.01.009
Influence of PEG in PEG-PLGA microspheres on particle properties and protein release.
J. Buske (2012)
10.2174/138920012798356934
PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery.
P. Milla (2012)
10.1016/0006-2952(93)90228-O
Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization.
L. Raveh (1993)
10.1016/j.phrs.2010.03.005
Targeting nanoparticles to cancer.
M. Wang (2010)
10.1016/B978-0-12-800159-2.00034-8
Chemical warfare agents and the nervous system
J. Liu (2015)
10.1016/j.cbi.2013.06.012
Progress in the development of enzyme-based nerve agent bioscavengers.
F. Nachon (2013)
10.1016/S0149-7634(05)80103-4
Enzymes as pretreatment drugs for organophosphate toxicity
B. Doctor (1991)
10.1016/j.etap.2004.12.048
Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of a common mechanism of action.
C. Pope (2005)
10.1016/j.jcis.2012.06.068
Insulin complexes with PEGylated basic oligopeptides.
D. Tsiourvas (2012)
10.1385/JMN:30:1:145
Bioscavenger for protection from toxicity of organosphosphorus compounds
A. Saxena (2007)
10.1016/j.jconrel.2010.06.003
Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol.
B. N. Novikov (2010)
10.1016/J.CBI.2005.10.024
Bioscavengers for the protection of humans against organophosphate toxicity.
B. Doctor (2005)
10.1016/0006-2952(91)90008-S
Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice.
Y. Ashani (1991)
10.1016/J.BIOMATERIALS.2005.05.042
Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution.
H. M. Aliabadi (2005)
10.1016/j.pharmthera.2014.11.011
Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses.
O. Lockridge (2015)
10.1016/j.jconrel.2014.06.046
PEG - a versatile conjugating ligand for drugs and drug delivery systems.
Atul Kolate (2014)
10.1016/j.jconrel.2014.04.017
Assessment of PEG on polymeric particles surface, a key step in drug carrier translation.
Jean-Michel Rabanel (2014)
10.2174/156800911796798896
Current targeting strategies for adenovirus vectors in cancer gene therapy.
X. Yao (2011)
10.1016/j.cbi.2010.01.005
Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system.
Andrea Gaydess (2010)
10.1016/J.CBI.2005.10.013
Polyethylene glycosylation prolongs the circulatory stability of recombinant human butyrylcholinesterase.
N. Chilukuri (2005)
10.1007/S00396-009-2131-Z
Protein-loaded PLGA–PEO blend nanoparticles: encapsulation, release and degradation characteristics
M. J. Santander-Ortega (2010)
10.1016/j.bcp.2011.09.019
Pretreatment with human serum butyrylcholinesterase alone prevents cardiac abnormalities, seizures, and death in Göttingen minipigs exposed to sarin vapor.
A. Saxena (2011)
10.1007/s00204-014-1204-z
Efficacy of the rePON1 mutant IIG1 to prevent cyclosarin toxicity in vivo and to detoxify structurally different nerve agents in vitro
F. Worek (2014)
10.1016/J.CBI.2005.10.021
Functional requirements for the optimal catalytic configuration of the AChE active center.
A. Shafferman (2005)
10.1177/12.3.219
A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES
M. Karnovsky (1964)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar